Proprietary Data Used to Highlight Likelihood of Drug Approval and Competitive Landscape

New York, April 6, 2005 – Revere Data, LLC, a fast-growing provider of independent research data and investment analytics, today announced a new Revere Report that identifies companies with expected FDA drug approval decision dates (commonly known as PDUFA dates) in the next three months. Data from Revere’s patented classification system and proprietary drug pipeline database is included to provide insights into each drug candidate’s likelihood of approval and the competition it will face.

The FDA Approval Decisions Report is designed to generate ideas for trading and investment opportunities in the Biopharmaceuticals sector. The Report is available on Revere’s website.

"For investors monitoring the drug development pipelines of pharmaceutical and biotech companies, no milestone is more influential than the PDUFA date," noted Brian Hill, Director of Research for Revere. "Using this calendar and Revere’s exclusive content, customers can quickly focus on companies that have potentially high-impact events on the horizon."

Specifically, the FDA Approval Decisions Report provides a three-month calendar of expected PDUFA dates, along with detail on whether each drug candidate:

1. utilizes a mechanism of action already approved by the FDA in other drugs

2. faces two or fewer alternative drugs with the same mechanism of action for the same indication

3. would be the first or second FDA-approved drug for the company

4. "Drugs that meet these criteria are more likely to gain approval, and to positively impact the company’s stock price when they do," explained Hill. "But attempting to track and assess them without Revere would be hugely time-consuming."

Companies profiled in the initial FDA Approval Decisions Report include Adolor, Alcon, Amylin Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, Par Pharmaceutical, and Pfizer.

"This new report showcases our unique strength in applying Revere’s classification system to mapping the drug pipelines of virtually all publicly traded Healthcare companies," said Glen Wolyner, Chief Executive Officer of Revere. "Each month, we can help investors pinpoint the upcoming drug approvals they need to watch most carefully."

Revere’s exclusive content on product and industry classification and on key business relationships is available both in datafeeds and in Revere’s own applications. Revere’s customers include sellside agency and proprietary traders, buyside traders, hedge fund managers, portfolio managers, equity analysts, and other professionals at leading financial institutions, along with competitive intelligence, business development, and strategy specialists at major corporations.

Become a bobsguide member to access the following

1. Unrestricted access to bobsguide
2. Send a proposal request
3. Insights delivered daily to your inbox
4. Career development